Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer

• Published in: Breast (Edinburgh) Vol. 54; pp. 303 - 310
• Main Authors: Porte, B., Carton, M., Lerebours, F., Brain, E., Loirat, D., Haroun, L., Bellesoeur, A., Bach Hamba, S., Kirova, Y., Cottu, P.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-12-2020; Elsevier
• Subjects: Advanced breast cancer; Endocrine therapy; Original; Palbociclib; Real-life; Endocrine therapy; Advanced breast cancer; Real-life; Palbociclib
• ISSN: 0960-9776; 1532-3080
• DOI: 10.1016/j.breast.2020.11.008

Palbociclib is indicated for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), in combination with endocrine therapy. Emerging real-life data suggest that the efficacy of a palbociclib-based therapy is highly conserved. We report the Institut Curie hospital experience.
We retrospectively reviewed all patients with HR + HER2- ABC treated with a palbociclib-based therapy as first or second line for ABC, with an initial prescription from November 2016 to December 2018. Clinical, laboratory and imaging data were retrieved from electronic records. Data lock was December 31st, 2019. Descriptive analyses, univariate and multivariate Cox regression analyses were performed.
We included 310 consecutive patients. Median age was 61.8 years old. Palbociclib was prescribed in first line in 225 patients (72.6%). Before palbociclib-based therapy initiation, 122 patients (39.3%) were endocrine naive, 96 (31.0%) endocrine sensitive and 92 (29.7%) endocrine resistant. Median follow-up was 20.7 months. Median progression free survival (PFS) was 23.4 months (95%CI: 21.6-NR) in endocrine naive patients, 22.7 months (95%CI: 14.7-NR) in endocrine sensitive, and 13.4 months (95%CI: 10.7–20.8) in endocrine resistant. At 12 months from the initiation of palbociclib, 94.5% of patients were alive. By multivariate analysis, poor prognosis factors for PFS were identified in the endocrine naive/sensitive population: initial ECOG status 2, previous endocrine therapy for ABC, 3 metastatic sites or more. Toxicity profile was similar to previously published data.
In a non-selected population of patients with HR + HER2- ABC, the efficacy and safety data are strikingly similar to those previously reported.
•Efficacy of palbociclib in advanced breast cancer in real-life is very close to that from the pivotal trials.•Long-term follow-up of patients treated with palbociclib show no cumulative adverse events.